ReviewEuropean journal of clinical investigation2026
Muscle health in the modern era of incretin-based therapies.
Review in European journal of clinical investigation, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Obesity medications and precision nutrition: synergistic interventions and integrated approach in obesity management.Current obesity reports · 2026Review
- Muscle health in the modern era of incretin-based therapies.European journal of clinical investigation · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundIntentional weight loss improves obesity-related outcomes but reduces lean body mass, raising concern about skeletal muscle mass, function and long-term health. GLP-1 receptor agonists (GLP-1RAs) produce clinically meaningful weight loss primarily by lowering energy intake and slowing gastric emptying, with additional benefits on insulin sensitivity and inflammation.
objectiveTo clarify GLP-1RAs' effects on skeletal muscle tissue, body composition and physical function by reviewing preclinical and clinical evidence.
findingsAcross randomized and controlled studies, GLP-1RAs reduce fat mass more than lean body mass. Functional measures appear preserved. Preclinical and early clinical data suggest improvements in muscle quality (microvascular recruitment, mitochondrial efficiency, reduced intramuscular fat) rather than hypertrophy.
conclusionsGLP-1RA-induced weight loss is largely fat mass with modest absolute lean body mass decline and no consistent deterioration in strength or function. Progressive resistance training, adequate/high-quality protein and periodic monitoring of body composition and performance should accompany therapy, especially in higher-risk patients.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.